ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cabergoline

Also written as “Cabergoline tablets test formulation”, “Cabergoline tablets reference formulation” and “Cabergoline tablets”.

Its studies are mostly in Hyperprolactinemia · Restless Legs Syndrome · Adrenocortical Hyperfunction · Acromegaly · Fasting, led by 4 companies.

Drug pageCabergoline: every studyAll 52 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 3, 20258 company-led studies, 2 open or runningNext primary completion: Nov 21, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceuticalits history only22 open or runningphase 3since Aug 3, 2025May 29, 2025Nov 21, 2026phase 3 · NCT07124221
Novartis20 open or runningphase 4since Sep 13, 2006Sep 13, 2006none ahead
Par Healthits history only20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Pfizerits history only20 open or runningphase 3since Feb 19, 2008Feb 19, 2008none ahead

Also a collaborator on its studies: Anapharm.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2006First study: phase 4 study in AcromegalyFirst studyNCT00376064 · 20 enrolled · Germany
  2. Jun 10, 2013Phase 2 study in Adrenocortical HyperfunctionNCT01915303 · 68 enrolled · United States, Argentina, Belgium and more

TargetBeta

DRD2 →read by rule
“Dopamine D2 receptor agonist”ChEMBL 37, by rule

Other programs on DRD2

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
rotigotineruleUCBphase 464
lurasidoneruleSumitomo Pharmaphase 452
PramipexoleruleBoehringer Ingelheimphase 444
iloperidoneruleVanda Pharmaceuticalsphase 415
cariprazineruleAbbViephase 341
lumateperoneruleJohnson & Johnsonphase 325
pridopidineruleprileniaphase 310

Studies

All 2 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01915303Adrenocortical Hyperfunction · United States, Argentina, Belgium and more2TerminatedSep 5, 201668
NCT00376064Acromegaly · Germany4CompletedJan 201020

How it is read

Names in the registry

  • “Cabergoline”, 3 entries
  • “Cabergoline tablets test formulation”, 1 entry
  • “Cabergoline tablets reference formulation”, 1 entry
  • “Cabergoline tablets”, 1 entry
  • “Pasireotide with or without cabergoline”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.